Circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A Dutch Uro-Oncology Study Group side-study

Trial Profile

Circulating tumor cells (CTCs) in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A Dutch Uro-Oncology Study Group side-study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Budesonide; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Oct 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
    • 04 Oct 2016 Efficacy and safety results (n=227) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 20 Mar 2014 Not official study title and study status estimated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top